Standout Papers

CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell ma... 2010 2026 2015 2020 583
  1. CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability (2010)
    Brian J. Lannutti, Sarah Meadows et al. Blood
  2. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity (2010)
    Amie S. Corbin, Anupriya Agarwal et al. Journal of Clinical Investigation
  3. OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CML (2013)
    Julia E. Maxson, Jason Gotlib et al. New England Journal of Medicine

Immediate Impact

3 by Nobel laureates 35 from Science/Nature 65 standout
Sub-graph 1 of 20

Citing Papers

The changing landscape of atherosclerosis
2021 StandoutNature
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
2020 Standout
3 intermediate papers

Works of Marc Loriaux being referenced

Survey of Activated FLT3 Signaling in Leukemia
2011
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
2010 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Marc Loriaux 2158 2060 1956 96 4.5k
Christopher A. Eide 2258 1527 1556 92 3.8k
Nikolas von Bubnoff 1933 1309 1102 134 4.0k
Ronald Paquette 3179 2321 1509 117 4.9k
Philip Beer 2223 2674 2336 86 4.5k
Katherine R. Calvo 2311 1378 1621 140 4.9k
Johan Richter 1683 1133 1502 141 4.1k
Taghi Manshouri 3064 3113 2995 140 6.1k
Thomas Mercher 1934 1904 2341 53 3.9k
Y. Lynn Wang 1044 1756 1494 109 3.4k
Clayton A. Smith 2837 1110 2665 128 5.3k

All Works

Loading papers...

Rankless by CCL
2026